CN106511793A - Medicinal and dietary composition having effect of decreasing blood fat and application of composition - Google Patents
Medicinal and dietary composition having effect of decreasing blood fat and application of composition Download PDFInfo
- Publication number
- CN106511793A CN106511793A CN201610919796.XA CN201610919796A CN106511793A CN 106511793 A CN106511793 A CN 106511793A CN 201610919796 A CN201610919796 A CN 201610919796A CN 106511793 A CN106511793 A CN 106511793A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- powder
- medicinal
- drinking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 230000000694 effects Effects 0.000 title claims abstract description 22
- 210000004369 blood Anatomy 0.000 title claims abstract description 19
- 239000008280 blood Substances 0.000 title claims abstract description 19
- 230000003247 decreasing effect Effects 0.000 title abstract 5
- 235000007882 dietary composition Nutrition 0.000 title abstract 5
- 239000000843 powder Substances 0.000 claims abstract description 47
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 6
- 230000035622 drinking Effects 0.000 claims description 25
- 235000008216 herbs Nutrition 0.000 claims description 25
- 230000010354 integration Effects 0.000 claims description 25
- 239000002671 adjuvant Substances 0.000 claims description 2
- 241000219304 Portulacaceae Species 0.000 claims 4
- 244000269722 Thea sinensis Species 0.000 claims 4
- 235000013312 flour Nutrition 0.000 claims 1
- 235000019197 fats Nutrition 0.000 abstract description 19
- 244000234609 Portulaca oleracea Species 0.000 abstract description 12
- 244000075850 Avena orientalis Species 0.000 abstract description 6
- 235000007319 Avena orientalis Nutrition 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 6
- 244000183685 Citrus aurantium Species 0.000 abstract description 5
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 abstract description 4
- 235000007716 Citrus aurantium Nutrition 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 235000020778 linoleic acid Nutrition 0.000 abstract 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 abstract 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 241001122767 Theaceae Species 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 235000013616 tea Nutrition 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000009200 high fat diet Nutrition 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 244000104272 Bidens pilosa Species 0.000 description 1
- 235000010662 Bidens pilosa Nutrition 0.000 description 1
- 241000209202 Bromus secalinus Species 0.000 description 1
- 102100030797 Conserved oligomeric Golgi complex subunit 2 Human genes 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000920113 Homo sapiens Conserved oligomeric Golgi complex subunit 2 Proteins 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 244000228367 Lewisia rediviva Species 0.000 description 1
- 235000007279 Lewisia rediviva Nutrition 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 241001018563 Nekemias grossedentata Species 0.000 description 1
- 241000219099 Parthenocissus quinquefolia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a medicinal and dietary composition having an effect of decreasing blood fat. An active ingredient of the composition is prepared from the following raw materials in parts by weight: 200-400 parts of powdery phospholipid, 50-70 parts of ampelopsin grossedentata powder, 70-90 parts of powder of seeds of portulaca oleracea L., 40-60 parts of Citrus aurantium L.var.amara Engl. powder and 200-300 parts of oat powder; and the active ingredient can be used for preparing medicines, health care products or foods having the effect of decreasing blood fat. The medicinal and dietary composition provided by the invention completely consists of foods or medicinal and dietary medicinal materials as components on the basis of scientific and reasonable compatibility, the composition is free from chemically synthesized components and free from toxic and side effects, and the composition is capable of treating both symptoms and root causes and taking the relatively good effect of decreasing blood fat. The medicinal and dietary composition provided by the invention is good in efficacy, low in cost and simple in preparation process, and the composition is capable of reducing production cost and relieving economic burden in patients; and with the adoption of seeds of portulaca oleracea L. which is rich in such components as polyunsaturated fatty acids, linoleic acid and the like in the medicinal materials of the medicinal and dietary composition provided by the invention, the effect of the composition of decreasing blood fat is enhanced.
Description
(1) technical field
The present invention relates to a kind of integration of drinking and medicinal herbs composition and its application, and in particular to a kind of food of the medicine with effect for reducing fat is same
Source composition and its application.
(2) background technology
Hyperlipidemia, also known as hyperlipoprotememia, is the used title of abnormalities of sugar/lipid metabolism, refer mainly to serum total cholesterol (TC),
The cardiovascular correlation disease of the horizontal abnormalities such as triglycerides (TG), serum High Density Lipoprotein Cholesterol (HDL-C) and caused body
Disease, it is clinically relatively conventional at present.Investigation in 2006 shows that China has 2,500,000～3,000,000 people to die from cardiovascular disease every year
Disease.In recent years, this kind of disease has rapid ascendant trend, and the age fallen ill is presented rejuvenation.Therefore, find highly effective and safe
Blood fat reducing food, particularly develops a kind of natural origin, and the health food with effect for reducing blood fat of medicine-food two-purpose has important
Meaning.
(3) content of the invention
It is an object of the invention to provide a kind of integration of drinking and medicinal herbs composition with effect for reducing fat and its application, described medicine food
Consanguinity association thing with powder phospholipid, vine tea powder, purslane seed powder, from generation to generation pollen, oatmeal by raw material ECDC reason compatibility make, should
Integration of drinking and medicinal herbs composition shows notable health-care efficacy in terms of the diseases such as blood fat, preventing and treating angiocarpy are adjusted, and has anti-oxidant
Property strong and security performance it is high the features such as, hyperlipemia rat Research of Animal Model for Study shows that there is the integration of drinking and medicinal herbs composition reducing blood lipid to make
With.
The present invention is adopted the following technical scheme that：
A kind of integration of drinking and medicinal herbs composition with effect for reducing fat, its active ingredient are made up of the raw material of following weight portion：
200～400 parts of powder phospholipid, 50～70 parts of vine tea powder, from generation to generation 70～90 parts of purslane seed powder, pollen 40～60
Part, 200～300 parts of oatmeal.
It is particularly preferred, the integration of drinking and medicinal herbs composition with effect for reducing fat of the present invention, its active ingredient is by weighing as follows
The raw material composition of amount part：
240 parts of powder phospholipid, 60 parts of vine tea powder, from generation to generation 80 parts of purslane seed powder, 50 parts of pollen, 250 parts of oatmeal.
In integration of drinking and medicinal herbs composition with effect for reducing fat of the present invention, in addition to described active ingredient, also
The acceptable edible adjuvant of human body, such as beta-schardinger dextrin etc. can be included.
In the present invention, the source of each raw material and its pharmacological action are described below：
Powder phospholipid：With soybean oil residue as raw material, by purification step systems such as de-oiling well known in the prior art, removal of impurities
It is standby；There are regulation blood fat, brain tonic and intelligence development, prevent and treat the physiological functions such as fatty liver, anti-aging.
Vine tea：Vitaceae ampelopsis ampelopsis grossdentata (Ampelopsis grossedentata (Hand-Mazz)
W.T.wan tender leaf), wherein containing abundant flavones, especially with dihydromyricetin cellulose content highest；Disappear with clearing heat and detoxicating, sterilized
The multiple efficacies such as scorching, analgesia detumescence, blood fat-reducing blood pressure-decreasing, prevention cardiovascular and cerebrovascular disease, raising body immunity.
Purslane seed：The seed of Portulacaceae portulaca purslane (Portulaca oleracea L.)；Dent
Amaranth herb hyoscine, have clearing heat and promoting diuresis, removing toxicity for detumescence, anti-inflammatory, quench the thirst, diuresis.
Bitter orange flower：Rutaceae citrus plant bitter orange flower (Bidens pilosa L.) bud；For the conventional grass of folks of china
Medicine, has qi-regulating width chest, the effect for the preventing or arresting vomiting that whets the appetite.
Oat：The seed of grass oat (Avena sativa L.),《Compendium of Materia Medica》In be referred to as bromegrass, open country
Wheat；Oat property sweet taste, the beneficial spleen nourishing heart of energy, arrest sweating, has higher nutritive value, can be used for body void spontaneous perspiration, night sweat or lung knot
Core patient.
In each raw material powder of the present invention, powder phospholipid, oatmeal can directly buy standard plant powder from market；Horse
Bitterroot seed, bitter orange flower, vine tea all have standard plant raw material, and powder preparation is played in further Jing conventional processing.
Integration of drinking and medicinal herbs composition with effect for reducing fat of the present invention, can be prepared into by conventional production process micro-
Capsule, tablet or granular preparation are directly applied.The present invention is tested by rat high blood lipid model, it was demonstrated that the integration of drinking and medicinal herbs composition
With blood fat reducing function.
The beneficial effects of the present invention is：
(1) integration of drinking and medicinal herbs composition components of the present invention all come from food or medicine-food two-purpose medicinal material, Jing science
Reasonable compatibility is made, and without chemical industry synthesis composition, has no toxic side effect, treats both principal and secondary aspect of disease, with preferable effect for reducing blood fat.
(2) integration of drinking and medicinal herbs composition good drug efficacy of the present invention, low cost, preparation process is simple, reduce production cost, mitigate
Patient economy burden.
(3) using this composition of purslane seed in the medicinal material of integration of drinking and medicinal herbs composition of the present invention, wherein rich in how unsaturated
The compositions such as aliphatic acid, linoleic acid, enhance this composition Hypolipidemic efficacy.
(4) illustrate
Fig. 1：Impact of the present composition to High fat diet rats serum TG levels in embodiment 3；
Fig. 2：Impact of the present composition to High fat diet rats serum hdl C levels in embodiment 3；
Fig. 3：Impact of the present composition to High fat diet rats serum TC level in embodiment 3.
(5) specific embodiment
Below by specific embodiment, the present invention is further illustrated, but protection scope of the present invention is not limited in
This.
In following examples, used raw material is each derived from：
Powder phospholipid comes from Jiangsu Man bio tech ltd；
Vine tea is provided by Jing Xiang vine teas Co., Ltd of Hunan Province；
Purslane seed is purchased from the garden was gay with bloosoms of every bue for Shuyang County nursery stock field；
Bitter orange flower is purchased from Anguo City Qi Ao prepared slices of Chinese crude drugs Co., Ltd；
Oatmeal is purchased from Inner Mongolia SaiBao Oat Food Co., Ltd..
Embodiment 1：A kind of preparation of the integration of drinking and medicinal herbs composition with effect for reducing fat
Mix each raw material according to following weight：
Powder phospholipid 400g, vine tea powder 70g, purslane seed powder 80g, from generation to generation pollen 40g, oatmeal 300g.
Carry out dispensing 1g/ bags after above-mentioned raw materials are mixed.Recommend instructions of taking：Twice daily, every time 1 bag.
Embodiment 2：A kind of preparation of the integration of drinking and medicinal herbs composition grain with effect for reducing fat
Mix each raw material according to following weight：
Powder phospholipid 1000g, vine tea powder 300g, purslane seed powder 400g, from generation to generation pollen 300g, oatmeal 1300g.
Above-mentioned each raw material is mixed, 2000g beta-schardinger dextrins are added, is mixed, granulation.3g/ bags are distributed into, recommend the side of taking
Method, twice daily, 1 bag every time.
Embodiment 3：The reducing blood lipid pharmacological research of integration of drinking and medicinal herbs composition of the present invention
Zoopery
SD rats, 180 ± 20g of body weight, are randomly divided into 4 groups by 48, and control group, hyperlipidemia model group, composition A groups (are implemented
Prepared by example 1,25mg/kg.bw) and composition B groups (prepared by embodiment 2,45mg/kg.bw), powder phospholipid C group (45mg/
Kg.bw), vine tea powder D groups (45mg/kg.bw), in addition to control group, all animals are fed with high lipid food, and control group is fed with basis
Feed.Composition A groups, composition B groups, powder phospholipid C groups, vine tea powder D groups by gastric infusion, once a day, control group and mould
Type group gives saline solution by gavage.Serum total cholesterol (TC), HDL-C (HDLC) and triglyceride
(TG) detected with full automatic biochemical apparatus.
Impact of the present composition to hyperlipemia rat Biochemical Indices In Serum is as shown in Figure 1, 2, 3.
Impact of the present composition to hyperlipemia rat serum triglyceride level is as shown in Figure 1.As shown in Figure 1, exist
After high lipid food is fed 9 weeks, the TG levels of model group animal are apparently higher than control group.After the present composition is given, serum
TG levels are substantially reduced, and are close to normal level, at the same be used alone powder phospholipid and vine tea powder compares that more to reduce serum sweet
Oily three esters.
Impact of the present composition to High fat diet rats serum hdl C levels is as shown in Figure 2.As shown in Figure 2, giving this
After inventive composition, rat blood serum HDLC levels also have the trend of reduction, compare effect with powder phospholipid is used alone with vine tea powder
Fruit is more preferably.
Impact of the present composition to High fat diet rats serum TC level is as shown in Figure 3.From the figure 3, it may be seen that in high lipid food
After feeding 9 weeks, the TC levels of model group animal are apparently higher than control group.After the present composition of various dose is given, blood
Clear TC levels are substantially reduced, and have compared clear superiority with powder phospholipid is used alone with vine tea powder.
To sum up, the present composition has TC, TG, LDLC level for substantially reducing hyperlipidemia ratses serum, shows combination
Thing has the effect of reducing blood lipid.
Claims (5)
1. a kind of integration of drinking and medicinal herbs composition with effect for reducing fat, it is characterised in that the integration of drinking and medicinal herbs composition it is effective into
Divide and be made up of the raw material of following weight portion：
200～400 parts of powder phospholipid, 50～70 parts of vine tea powder, from generation to generation 70～90 parts of purslane seed powder, 40～60 parts of pollen, swallow
200～300 parts of flour.
2. integration of drinking and medicinal herbs composition as claimed in claim 1, it is characterised in that the active ingredient of the integration of drinking and medicinal herbs composition
It is made up of the raw material of following weight portion：
240 parts of powder phospholipid, 60 parts of vine tea powder, from generation to generation 80 parts of purslane seed powder, 50 parts of pollen, 250 parts of oatmeal.
3. integration of drinking and medicinal herbs composition as claimed in claim 1, it is characterised in that the integration of drinking and medicinal herbs composition is by following weight
The acceptable edible adjuvant composition of raw material and human body of part：200～400 parts of powder phospholipid, 50～70 parts of vine tea powder, purslane seed
70～90 parts of powder, from generation to generation 40～60 parts of pollen, 200～300 parts of oatmeal.
4. integration of drinking and medicinal herbs composition as claimed in claim 1, it is characterised in that the integration of drinking and medicinal herbs composition is by following weight
The raw material composition of part：200～400 parts of powder phospholipid, 50～70 parts of vine tea powder, from generation to generation 70～90 parts of purslane seed powder, pollen 40
～60 parts, 200～300 parts of oatmeal.
5. the integration of drinking and medicinal herbs composition as described in any one of Claims 1 to 4 is preparing the medicine with blood fat reducing function, health care
Application in product or food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610919796.XA CN106511793A (en) | 2016-10-21 | 2016-10-21 | Medicinal and dietary composition having effect of decreasing blood fat and application of composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610919796.XA CN106511793A (en) | 2016-10-21 | 2016-10-21 | Medicinal and dietary composition having effect of decreasing blood fat and application of composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106511793A true CN106511793A (en) | 2017-03-22 |
Family
ID=58291731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610919796.XA Pending CN106511793A (en) | 2016-10-21 | 2016-10-21 | Medicinal and dietary composition having effect of decreasing blood fat and application of composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106511793A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1363367A (en) * | 2002-01-18 | 2002-08-14 | 北京大学 | Active components of Chinese-medicinal medicine with weight-losing and hypolipemic actions and its relative medicine |
| CN101361886A (en) * | 2007-08-07 | 2009-02-11 | 北京北大维信生物科技有限公司 | Chinese herbal medicine extract with lipase activity inhibition and new use thereof |
| CN103566150A (en) * | 2013-10-10 | 2014-02-12 | 北京昊源康科技有限公司 | Medicine and food homologous food composition with blood fat reducing function as well as application thereof |
| CN104068142A (en) * | 2013-03-30 | 2014-10-01 | 廖宣植 | Health-care tea with effects of reducing fat and losing weight and preparing method of health-care tea |
| CN104138468A (en) * | 2014-07-29 | 2014-11-12 | 卞佳林 | Application of traditional Chinese medicine compound in preparing of lipid-lowering drugs |
| CN104857121A (en) * | 2015-05-05 | 2015-08-26 | 青岛市市立医院 | Drug combination for curing hyperlipidemia and application thereof |
| CN105596576A (en) * | 2015-12-30 | 2016-05-25 | 吉林省现代中药工程研究中心有限公司 | Tea bag with blood fat reducing action |
-
2016
- 2016-10-21 CN CN201610919796.XA patent/CN106511793A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1363367A (en) * | 2002-01-18 | 2002-08-14 | 北京大学 | Active components of Chinese-medicinal medicine with weight-losing and hypolipemic actions and its relative medicine |
| CN101361886A (en) * | 2007-08-07 | 2009-02-11 | 北京北大维信生物科技有限公司 | Chinese herbal medicine extract with lipase activity inhibition and new use thereof |
| CN104068142A (en) * | 2013-03-30 | 2014-10-01 | 廖宣植 | Health-care tea with effects of reducing fat and losing weight and preparing method of health-care tea |
| CN103566150A (en) * | 2013-10-10 | 2014-02-12 | 北京昊源康科技有限公司 | Medicine and food homologous food composition with blood fat reducing function as well as application thereof |
| CN104138468A (en) * | 2014-07-29 | 2014-11-12 | 卞佳林 | Application of traditional Chinese medicine compound in preparing of lipid-lowering drugs |
| CN104857121A (en) * | 2015-05-05 | 2015-08-26 | 青岛市市立医院 | Drug combination for curing hyperlipidemia and application thereof |
| CN105596576A (en) * | 2015-12-30 | 2016-05-25 | 吉林省现代中药工程研究中心有限公司 | Tea bag with blood fat reducing action |
Non-Patent Citations (1)
| Title |
|---|
| 王也 等: "降血脂类中药的研究进展", 《中医药学刊》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6027573B2 (en) | Hangover prevention or treatment composition | |
| CN103766902A (en) | Powder with effect of helping to lower blood lipid and preparation method of powder | |
| WO2005074960A1 (en) | Physiologically functional drinks and compositions | |
| CN101766274B (en) | Antioxidant functional food composition containing bamboo-leaves flavones | |
| CN105851360A (en) | Preparation method for health food capable of substantially improving blood sugar and blood fat and rapidly supplementing trace elements essential for human body | |
| EP2891496B1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING COMPLEX EXTRACT OF CRATAEGI FRUCTUS and CITRI PERICARPIUM AS AN ACTIVE INGREDIENT FOR TREATING OR PREVENTING OBESITY OR LIPID-RELATED METABOLIC DISEASES | |
| JP2011032217A (en) | Fat absorption inhibitor | |
| CN103750464A (en) | Asarum sagittarioides intelligence-improving functional beverage and preparation method thereof | |
| CN101658641A (en) | Health-care preparation containing gastrodia tuer, folium cortex eucommiae, and Ilex latifolia thumb and preparation method thereof | |
| CN105101817B (en) | Edible composition and preparation method thereof and the food comprising said composition | |
| KR20130066535A (en) | Composition comprising water extracts from pleurotus eryngii var. ferulea (pf.). for treating or preventing hyperlipidemia | |
| JP7090849B2 (en) | Liver function improving composition and liver function improving food composition | |
| CN106511793A (en) | Medicinal and dietary composition having effect of decreasing blood fat and application of composition | |
| CN103989206B (en) | A kind of decompression dietary supplements containing GABA and its preparation method | |
| CN104474337B (en) | A kind of preparation method containing in green-tea extract into health instant powder | |
| KR20150102432A (en) | Choco pill with ultrafine gigantic angelica powder and manufacturing method thereof | |
| CN103734420B (en) | Rosaroxbunghii and dianthus chinensis tea and making method for same | |
| JP7122727B2 (en) | Beverage containing ferulic acid | |
| KR20080090101A (en) | Nutraceuticals using marine, plant capsosiphon fulvescens(mesangi) and its process | |
| CN106999524B (en) | Composition containing ginseng seed oil for preventing and treating prostatic hyperplasia | |
| Troup | The whole food health advantage: improving health outcomes | |
| LU501691B1 (en) | Composition with weight-losing and lipid-lowering activity and product | |
| WO2018072341A1 (en) | Pharmaceutical agent for treating aids or tumor by means of oral administration and external application in combination | |
| US20240000091A1 (en) | Nutritional supplement for lactating mothers | |
| CN103156120A (en) | Gynostemma pentaphyllum nutritional diet porridge |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |